Garadacimab for the prevention of recurrent attacks of hereditary angioedema in patients 12 years of age and older

2 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

MHRA approves nogapendekin alfa inbakicept to treat adult patients with non-muscle invasive bladder cancer 

4 July 2025 - The MHRA has today approved nogapendekin alfa inbakicept (Anktiva) for adults with BCG unresponsive non-muscle invasive bladder ...

Read more →

Teprotumumab for the treatment of patients with thyroid eye disease

2 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

Adagrasib for adults with previously treated, advanced, KRAS G12C mutation positive non-small-cell lung cancer

2 July 2025 - NICE is unable to make a recommendation on the use of adagrasib (Krazati) for the second-line treatment ...

Read more →

NICE welcomes the inclusion of measures for equal treatment of medicines and health technologies

1 July 2025 - The new approach will ensure that high impact devices, diagnostics and digital tools recommended by NICE, that ...

Read more →

Pegzilarginase for the treatment of patients 2 years of age and older with arginase-1 deficiency

26 June 2025 - NICE has published additional draft guidance consultation on the use of pegzilarginase in the NHS in ...

Read more →

MHRA approves UK’s first anti-PD-1 monoclonal antibody for treatment of aggressive form of lung cancer

20 June 2025 - The MHRA has today approved serplulimab (Hetronifly) to treat adults with extensive-stage small cell lung cancer, which ...

Read more →

Final draft guidance finds benefits of two treatments for patients with Alzheimer’s disease remain too small to justify the additional cost to the NHS

19 June 2025 - The benefits from donanemab (Kisunla; Eli Lilly) and lecanemab (Leqembi; Eisai) - remain too small to justify ...

Read more →

Tislelizumab for the treatment of adults with advanced non-small-cell lung cancer after platinum-based chemotherapy

19 June 2025 - NICE is unable to make a recommendation on the use of tislelizumab (Tevimbra) for the treatment of ...

Read more →

Atezolizumab for the adjuvant treatment of patients with resected non-small-cell lung cancer

19 June 2025 - NICE has published final evidence-based recommendations on the use of atezolizumab (Tecentriq) for the adjuvant treatment ...

Read more →

Obecabtagene autoleucel for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukaemia

13 June 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

NICE leads the way in approving breakthrough treatment for multiple myeloma

13 June 2025 - People in England will become the first in the world to receive belantamab mafodotin for this indication ...

Read more →

MHRA approves polihexanide to treat acanthamoeba keratitis

23 May 2025 - The Medicines and Healthcare products Regulatory Agency (MHRA) has approved polihexanide (Akantior) to treat acanthamoeba keratitis. ...

Read more →

Over 4,200 people set to benefit after we recommend daily pill to treat rare chronic kidney disease

23 May 2025 - New treatment sparsentan has been found to slow down the progression of kidney damage, which will change ...

Read more →

Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

22 May 2025 - Dostarlimab, when used in combination with platinum-based chemotherapy, can be used as an option for the ...

Read more →